

October 17, 2005

A Petition for a Preliminary Injunction filed by Pfizer about Amlodin

Sumitomo Chemical Company (Sumitomo Chemical) has been notified by the attorney of Pfizer (Pfizer Limited and Pfizer Corp. collectively) that Pfizer recently filed a petition at the Tokyo District Court for a preliminary injunction, calling for return to Pfizer of medical data and other information regarding Amlodin (Generic name: Amlodipine Besilate, a therapeutic drug for hypertension and angina pectoris) in relation to the transfer of the Amlodin business from former Sumitomo Pharmaceuticals Company (Sumitomo Pharmaceuticals), a licensee of Pfizer's Amlodin technology, to Dainippon Sumitomo Pharma (DSP) that has been established by the merger of Sumitomo Pharmaceuticals and Dainippon Pharmaceutical Company.

For DSP to succeed to the Amlodin license agreement, Sumitomo Pharmaceuticals assigned the license agreement, pursuant to provisions thereof, to its parent company, Sumitomo Chemical, who then granted a sub-license to a newly-formed subsidiary, DSP. Pfizer claims, however, that the Amlodin license agreement has been terminated as the licensee Sumitomo Pharmaceuticals no longer exists as a result of the merger, thus launching these legal proceedings.

Sumitomo Chemical firmly believes, based on the results of thorough studies including those by its external lawyers both in Japan and England, that the legitimacy of the Company's position will be fully affirmed by the Court and that DSP will be able to continue undertaking the Amlodin business with no adverse impact on its earnings